{"nctId":"NCT01617655","briefTitle":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)","startDateStruct":{"date":"2012-06"},"conditions":["Hypercholesterolaemia"],"count":107,"armGroups":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (for alirocumab)","Drug: Lipid Modifying Therapy (LMT)"]},{"label":"Alirocumab 150 mg Q2W","type":"EXPERIMENTAL","interventionNames":["Drug: Alirocumab","Drug: Lipid Modifying Therapy (LMT)"]}],"interventions":[{"name":"Alirocumab","otherNames":["SAR236553","REGN727","Praluent"]},{"name":"Placebo (for alirocumab)","otherNames":[]},{"name":"Lipid Modifying Therapy (LMT)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Participants with heterozygous familial hypercholesterolemia who were not adequately controlled with their lipid-modifying therapy.\n\nExclusion criteria:\n\n* Age \\< 18 years\n* LDL-C \\< 160 mg/dL (\\< 4.14 mmol/L) at the screening visit (Week-3).\n* Fasting serum triglycerides \\> 400 mg/dL (\\> 4.52 mmol/L) during the screening period.\n* Known history of homozygous familial hypercholesterolemia.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis","description":"Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"4.9"},{"groupId":"OG001","value":"-45.7","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"5"},{"groupId":"OG001","value":"-45.5","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"4.6"},{"groupId":"OG001","value":"-46.9","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"4.6"},{"groupId":"OG001","value":"-46.9","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.7","spread":"3.8"},{"groupId":"OG001","value":"-39","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.7","spread":"3.9"},{"groupId":"OG001","value":"-38.9","spread":"2.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":"4.3"},{"groupId":"OG001","value":"-41.9","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"4.3"},{"groupId":"OG001","value":"-41.7","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"3.6"},{"groupId":"OG001","value":"-33.2","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9","spread":"3.7"},{"groupId":"OG001","value":"-39.2","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.9","spread":"4.3"},{"groupId":"OG001","value":"-41.4","spread":"3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"3.5"},{"groupId":"OG001","value":"-33","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from week 4 to week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"5.9"},{"groupId":"OG001","value":"-42.1","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis","description":"Very high CV risk participants: Heterozygous Familial Hypercholesterolemia (heFH) participants with coronary heart disease (CHD) or CHD risk equivalents. High CV risk participants: heFH participants without CHD or CHD risk equivalents. CHD risk equivalent: peripheral arterial disease, ischemic stroke, moderate chronic kidney disease (estimated glomerular filtration rate, 30 to \\<60 ml/minute/1.73 m\\^2 of body-surface area), or diabetes mellitus plus 2 or more additional risk factors (hypertension; ankle-brachial index of â‰¤0.90; microalbuminuria, macroalbuminuria, or a urinary dipstick result of \\>2+ protein; preproliferative or proliferative retinopathy or laser treatment for retinopathy; or a family history of premature CHD). Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"41.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On-Treatment Analysis","description":"Adjusted percentages at Week 24 from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"41.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.7","spread":"5"},{"groupId":"OG001","value":"-23.5","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"2.7"},{"groupId":"OG001","value":"7.5","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"4.8"},{"groupId":"OG001","value":"-10.5","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"2.1"},{"groupId":"OG001","value":"5.6","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis","description":"Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"5.1"},{"groupId":"OG001","value":"-23.2","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"3.4"},{"groupId":"OG001","value":"7.9","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis","description":"Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"5.1"},{"groupId":"OG001","value":"-9.4","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.2"},{"groupId":"OG001","value":"4.6","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis","description":"Adjusted percentages at Week 24 from multiple imputation approach including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"32.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis","description":"Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"32.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"6.1"},{"groupId":"OG001","value":"-42.0","spread":"4.4"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 78 from MMRM model including all available post-baseline data from Week 4 to Week 78 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"6.4"},{"groupId":"OG001","value":"-37.9","spread":"4.5"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 78 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 78 i.e. up to 21 days after last injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"6.2"},{"groupId":"OG001","value":"-40.9","spread":"4.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":35},"commonTop":["Nasopharyngitis","Influenza","Injection site reaction","Diarrhoea","Myalgia"]}}}